Search

Displaying results 971 - 980 of 7283 in total
  1. Drug

    Tyrosine

    go.drugbank.com/drugs/DB00135
    ApprovedInvestigationalNutraceutical

    Tyrosine is a non-essential amino acid. In animals it is synthesized from [phenylalanine]. It is also the precursor of [epinephrine], thyroid hormones, and melanin.

    Mixtures: Appformin-D, Appbutamone-D
  2. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    As of December 11, 2017 the FDA approved Ferrer Internacional S.A.' … Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone

  3. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773]. … It is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement [A19276].

    Mixtures: BumP DHA, BumP DHACategories: Vitamin B Complex
  4. Drug

    Dalbavancin

    go.drugbank.com/drugs/DB06219
    ApprovedInvestigational

    Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072 … Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073].

  5. Indication

    Herpes simplex of the oral-labial

    go.drugbank.com/conditions/DBCOND0024319
    Drugs: Acyclovir
    Synonyms: Herpes simplex complex
  6. Drug

    Amivantamab

    go.drugbank.com/drugs/DB16695
    ApprovedInvestigational

    FDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with … [A235103,A235123] Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and were generally treated with platinum-based therapy.

  7. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    [A215107, A215112, A215117, A215127] Cedazuridine is a fluorinated tetrahydrouridine derivative specifically designed to inhibit CDA and facilitate oral administration of hypomethylating agents. … [A215082, A215092, A215097] Hypomethylating agents such as [decitabine] and [azacitidine] are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells.

  8. Drug

    Eucalyptus oil

    go.drugbank.com/drugs/DB11114
    Approved

    Eucalyptus oil is a distilled oil derived from the leaves of the tree Eucalyptus.

    Mixtures: Dr Waltons Vapor Rub, DT Vaporizing Chest RubCategories: Complex Mixtures
  9. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV. … Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  10. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. … [A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes.